Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

'Moonshot' Pilot Aims To Fast Track Cancer Immunotherapy Patents

Executive Summary

The Obama administration is offering biopharmaceutical companies and other inventors of cancer immunotherapies the opportunity to get their patent applications examined within 12 months under a special accelerated pilot program as part of the White House's $1bn National Cancer Moonshot initiative.

You may also be interested in...



Unifying On Immunotherapy: Will It Pay Off?

It's too early to know now whether the $250m billionaire tech entrepreneur Sean Parker is pumping into immunotherapy will pay off.

Can 'Moon Shot' Lift FDA Out Of Its Silos?

Even though the White House's "moon shot" initiative is focused on cancer, a key component of the program – a new multimillion-dollar FDA "virtual" center for excellence intended to expedite the development and regulatory review of new combination therapies – may be the force to lift the agency out of its silos so that drugs, devices and diagnostics intended to be used together for other types of diseases are not forced to undergo time-consuming separate assessments, said Ellen Sigal, founder and chair of the advocacy group Friends of Cancer Research (FOCR).

FDA 'Moon Shot' Center To Expedite Combo Cancer Drugs

The White House on Feb. 1 said President Barack Obama plans to spend $1bn to jumpstart his "moon shot" initiative to end cancer – a project being led by Vice President Joe Biden, who lost a son last year to a brain tumor.

Related Content

Topics

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel